In the world of maintenance, Taxanes don’t add survival benefits.
For low-risk patients, less radiation is as good, I would love to hear input from Rad Onc. I did notice that the Rad Oncs I work with are adopting this.
Although not a practice changing study, this study makes a few points that may be seen in future studies. In the setting of biochem-recurrent prostate cancer after RP, novel anti-androgen agents may replace ADT in combination with salvage XRT as they appear to be active and less toxic than traditional ADT. Low/Intermediate risk patients are likely of benefit with median PSA at accrual of 0.3 in this study, not unlike other similar studies. The role of combination anti-hormone therapy + salvage radiation seems to be solidifying.
Her2-low is here to stay. Expect further studies on Enhertu and Trodelvy on gastroesophageal Her-2 low patients. Response rates were modest however, so temper expectations as single agent therapy. I look forward to trials on future combination therapy.
Long term results on adjuvant FOLFIRINOX vs Gem in adjuvant pancreatic cancer. Although the survival benefit is quite significant (OS 53.5 vs 35.5 months respectively), I think the tell-tale numbers are the 5 year DFS being 26.1 vs 19%. The modest 7% curative benefit of triplet vs single agent chemotherapy highlights the difficulty in managing this disease and the continued need for investment in GI clinical trials.
Potentially practice changing trial from the EU on young, transplant eligible patients with MCL were all treated with first line chemo then randomized to Auto-HSCT +/- Ibrutinib. The addition of Ibrutinib to Auto-HSCT improved DFS compared to Auto-HSCT alone, and more interestingly patients treated Ibrutinib was better than those who had transplant but the data on the Ibrutinib vs traplant + Ibrutinib arms are premature. The addition of maintenance Rituximab did not seem to change any outcomes.
Older women with high-risk early breast cancer (EBC) benefit from adjuvant chemotherapy, but their treatment is frequently complicated by toxic side effects, resulting in dose reductions and delays.
Another new (potential) option for refractory ITP patients, efgartigimod is an IgG1-Fc-fragment engineered to reduce IgG autoantibody levels. 131 patients enrolled and 67% had >=3 prior lines of therapy, placebo controlled study. The study group had a 90% sustained platelet response, with >50% having plt counts of >30k >= 7 days apart.
Interesting non-operative approach for T1-2, N0-1, M0 TNBC or HER2+ breast cancer, 58 patients enrolled in this single center phase II out of MDA. 62% of patients had CR on biopsy after systemic therapy, if results hold true over a longer follow-up period this may be of significant impact.
Thought provoking retrospective study regarding primary RPLND for stage II NSGCT. Study found that after RPLND N1-3 disease had a recurrence rate of about 20%, which flattens at years 2 to 5, and in patients who recurred all were treated successfully with chemotherapy. Adjuvant chemotherapy is preferred on the NCCN for post-RPLND patients who are pN2-N3, however this suggests close surveillance may be an option in centers with high surgical expertise.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
